Valid Claim Forms Clause Samples

The 'Valid Claim Forms' clause defines the requirements that a claim form must meet to be considered acceptable under the agreement. Typically, this includes specifying the necessary information, such as the claimant's details, the nature of the claim, supporting documentation, and submission procedures. For example, a valid claim form might need to be completed in full, signed, and submitted within a certain timeframe. The core function of this clause is to ensure that claims are presented in a standardized and complete manner, which helps streamline the review process and reduces the risk of disputes over incomplete or improperly submitted claims.
Valid Claim Forms. To be considered “valid”, the Claim Form must contain the Settlement Class member’s name and mailing address, attestation of purchase(s) of Products as described in Section V(D) showing the number of Products purchased during the Class Period. Subject to Section V(H) herein, Claim Forms that do not meet the requirements set forth in this Agreement and in the Claim Form instructions may be rejected. The Settlement Administrator will determine a Claim Form’s validity. Where a good faith basis exists, the Settlement Administrator may reject a Claim Form for, among other reasons: (i) failure to attest to the purchase of the Products for personal, family or household use; (ii) attesting to purchase of products that are not covered by the terms of this Agreement; (iii) attesting to purchase of Products or products not during the Class Period;
Valid Claim Forms. 10.2.1. In order to receive a settlement payment pursuant to Section 4, a Settlement Class Member must submit a valid and timely claim form, substantially in the form attached hereto as side two of Exhibit A (“Claim Form”). A Claim Form is valid and timely if it: (a) includes the Settlement Class Member’s full name and address; (b) includes the telephone number called by Defendant to those Class Members; (c) is postmarked or submitted online by the last date of the 60-day “Claim Period,” as specified in the Claim Form and on the Mail Notice and Q&A Notice, which will be sixty (60) days following the Mailing of the Class Notice; (d) is correct and truthful; and (e) is not successfully challenged under Section 10.2.2 (“Valid Claim Form”) of this Settlement Agreement.
Valid Claim Forms. 10.2.1. In order to receive a settlement payment pursuant to Section 4, a Class Member must submit a valid and timely claim form, substantially in the form attached hereto as side two of Exhibit A (“Claim Form”). A Claim Form is valid and timely if it: (a) includes the Class Member’s full name and address; (b) includes the cellular telephone number called by QC during the Class Period; (c) is postmarked or submitted online by the last date of the 90-day “Claim Period,” as specified in the Claim Form and on the Mail Notice and Website Notice, which will be one hundred and twenty (120) days following entry of the Preliminary Approval Order); (d) is correct and truthful; and (e) is not successfully challenged under Section
Valid Claim Forms. To be considered Valid, the Claim Form must contain the Settlement Class member’s name and mailing address, attestation of purchase(s) of Products as described in subsection (D) showing the number of Products purchased during the Class Period. Subject to subsection (H), Claim Forms that do not meet the requirements set forth in this Agreement and in the Claim Form instructions may be rejected. The Settlement Administrator will determine a Claim Form’s validity. Where a good faith basis exists, the Settlement Administrator may reject a Claim Form for, among other reasons: (i) failure to attest to the purchase of the Products for personal, family or household use; (ii) attesting to purchase of products that are not covered by the terms of this Agreement; (iii) attesting to purchase of Products not during the Class Period; (iv) failure to provide adequate verification or additional information about the Claim pursuant to a request of the Settlement Administrator; (v) failure to fully complete and/or sign the Claim Form; (vi) failure to submit a legible Claim Form; (vii) submission of a fraudulent Claim Form; (viii) submission of a Claim Form that is duplicative of another Claim Form; (ix) submission of a Claim Form by a person who is not a member of the Settlement Class; (x) request by person submitting the Claim Form to pay funds to a person or entity that is not the member of the Settlement Class for whom the Claim Form is submitted; (xi) failure to submit a Claim Form by the end of the Claim Period; or (xii) failure to otherwise meet the requirements of this Agreement.
Valid Claim Forms. 10.2.1. In order to receive a settlement payment pursuant to Section 4, a Settlement Class Member must submit a valid and timely claim form, substantially in the form attached hereto as side two of Exhibit A (“Claim Form”). A Claim Form is valid and timely if it: (a) includes the Settlement Class Member's full name and address; (b) includes the cellular telephone number called by Super during the Class Period; (c) is postmarked or submitted online by September 22, 2022 “Claim Period,” as specified in the Claim Form and on the Mail Notice and Q&A Notice,; (d) is correct and truthful; and (e) is not successfully challenged under Section
Valid Claim Forms. 10.2.1. In order to receive a settlement payment pursuant to Section 4, a Class Member must submit a valid and timely claim form, substantially in the form attached hereto as side two of Exhibit A (“Claim Form”). An electronic copy of the claim form will be available on the Settlement Website. A Claim Form is valid and timely if it: (a) includes an attestation that Class Member’s cellular telephone number was called by Defendant during the Class Period where Class Member had not provided that number to Defendant prior to the call and that the Class Member is not: (1) a current or former employee, officer, director, agent, or legal representative of Defendant, (2) a current or former employee or legal professional of Class Counsel, or (3) a current or former employee of the Court; (b) includes the Class Member’s full name and address (at the time of the unwanted call during the Class Period); (c) is postmarked or submitted online by the last date of the 90-day “Claim Period,” as specified in the Claim Form and on the Mail Notice and Website Notice, which will be one hundred and twenty (120) days following entry of the Preliminary Approval Order); (d) is correct and truthful; and (e) is not excluded pursuant to Section 10.2.2 (“Valid Claim Form”).

Related to Valid Claim Forms

  • Valid Claim The term “Valid Claim” shall mean a claim of any issued and unexpired patent within the Licensed Patent Rights which has not been held unenforceable, unpatentable or invalid by a decision of a court or governmental body of competent jurisdiction in a ruling that is unappealed or unappealable. The term “Valid Claim” shall also include the claims of a pending patent application within the Licensed Patent Rights which have not been pending for a period of more than *** from the earliest priority date of the patent application.

  • Patent Rights The State and the U. S. Department of Transportation shall have the royalty free, nonexclusive and irrevocable right to use and to authorize others to use any patents developed by the Engineer under this contract.

  • Licensed Patents Immune Design, at its expense, shall have the first right to file, prosecute and maintain all Licensed Patents for which Immune Design has any exclusive rights under this Agreement using patent counsel reasonably approved by IDRI, including conducting any interferences, reexaminations, reissues, oppositions, or request for patent term extension relating thereto. Immune Design shall conduct such filing, prosecution and maintenance in good faith, taking into consideration IDRI’s retained rights hereunder, and consistent with reasonable business judgment, provide IDRI with all relevant or material documentation and proposed filing in the Territory so that IDRI may be concurrently and promptly informed of the continuing prosecution, and consult with IDRI with regards to Immune Design’s patent strategy with the Licensed Patents for which Immune Design has any exclusive rights under this Agreement. Licensed Patents in the name of IDRI shall remain in the name of IDRI. Immune Design shall use commercially reasonable efforts to ***, as applicable. To the extent such ***, Immune Design shall provide IDRI reasonable opportunity to review and comment on such prosecution efforts regarding such Licensed Patents in the Territory, and any IDRI comments will be reasonably considered in such prosecution efforts, and included to the extent affecting the IDRI Exclusive Field or IDRI Territory, as the case may be. If Immune Design determines in its sole discretion to abandon or not maintain any Licensed Patent for which Immune Design has any exclusive rights under this Agreement in the Territory, then Immune Design shall promptly provide IDRI with written notice of such determination at least sixty (60) days before any deadline for taking action to avoid abandonment and shall provide IDRI with the right, opportunity and reasonable assistance to prepare, file, prosecute and maintain such Licensed Patent in the applicable jurisdiction in IDRI’s sole discretion and at IDRI’s expense, provided that Immune Design shall provide such reasonable assistance at its own costs and expenses. If IDRI elects to prepare, file, prosecute and maintain such Licensed Patent in such jurisdiction for which Immune Design has any exclusive rights, then Immune Design’s license rights to such Licensed Patent in such country will become nonexclusive in such country under such Licensed Patent (and/or patent application). If IDRI desires Immune Design to file, in a particular jurisdiction, a Licensed Patent for which Immune Design has any exclusive rights under this Agreement that claims priority to another Licensed Patent for which Immune Design has any exclusive rights under this Agreement, IDRI shall provide written notice to Immune Design requesting that Immune Design file such patent application in such jurisdiction. If IDRI provides such written notice to Immune Design, Immune Design shall either (i) file and prosecute such patent application and maintain any patent issuing thereon in such jurisdiction and the Parties shall share the related costs and expenses (A) in countries *** on the basis of *** percent (***%) Immune Design: *** percent (***%) IDRI or (B) in countries within the IDRI Territory equally; or (ii) notify IDRI that Immune Design does not desire to file such patent application in such jurisdiction and provide IDRI with the opportunity to file and prosecute such patent application, provided that if IDRI files and prosecutes such patent application in such jurisdiction, then Immune Design’s license rights to such License Patent in such country will become nonexclusive in such country under such Licensed GLA Patent (and/or patent application). Immune Design shall be responsible for the costs and expenses incurred in connection with its own activities for filing, prosecuting and maintaining the Licensed Patents; IDRI shall be responsible for monitoring of such activities by IDRI.

  • Licensed Patent Rights The Licensee shall indemnify and hold the IC, its employees, students, fellows, agents, and consultants harmless from and against all liability, demands, damages, expenses, and losses, including but not limited to death, personal injury, illness, or property damage in connection with or arising out of:

  • Joint Patent Rights If not already established under the Research Collaboration Agreement, prior to either Party filing any Patent Right disclosing Joint Program Technology or Joint Probody Platform Improvements, the Parties shall establish a patent committee (the “Patent Committee”) comprised of at least one (1) representative of each Party for the purpose of facilitating the preparation, filing, prosecution, maintenance and defense of Joint Patent Rights. As agreed upon by the Parties, meetings of the Patent Committee may be face-to-face or may be conducted by teleconferences or videoconferences, from time to time as needed. The Patent Committee will be the forum through which the Parties coordinate their respective obligations to each other described in Sections 5.2.2 and 5.2.3 hereof and in this Section. In the event the Parties conceive or generate any Joint Program Technology or Joint Probody Platform Improvements, the Parties shall promptly meet to discuss and determine, based on mutual consent, whether to seek patent protection thereon, which Party will control filing, prosecution and maintenance of such patents and how to pay for the filing, prosecution and maintenance of such patents. It is presumed that ImmunoGen will control filing, prosecution and maintenance of Joint Patent Rights claiming Joint Program Technology or Joint Conjugation Probody Platform Improvements, and that CytomX will control filing, prosecution and maintenance of Joint Patent Rights claiming Joint Unconjugated Probody Platform Improvements. Neither Party will file any Joint Patent Right without the prior written consent of the other Party, which consent shall not be unreasonably withheld, conditioned or delayed. The Party controlling filing and prosecution of any such Joint Patent Right (a) shall keep the other Party informed regarding each Patent Right, (b) shall consider in good faith any recommendations made by the other Party in regard to the filing, prosecution or maintenance of any such Patent Right and (c) shall not unreasonably refuse to incorporate any recommendations made by the other Party in regard to such filing, prosecution or maintenance.